文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

经导管主动脉瓣置换术后利钠肽水平与后续临床结局的关联

Association of Natriuretic Peptide Levels After Transcatheter Aortic Valve Replacement With Subsequent Clinical Outcomes.
PubMed 文献 · JAMA Cardiol · 2020-01-01

本研究基于PARTNER IIA、PARTNER IIB及SAPIEN 3注册研究队列,纳入3391例接受TAVR的重度症状性主动脉瓣狭窄患者,分析术后BNP水平及变化与2年临床结局的关联。结果显示,TAVR术后30天BNP比值每增加1点与全因死亡、心血管死亡和再住院风险独立相关;出院时BNP比值≥2者,出院至30天BNP比值每降低1点与全因死亡风险降低相关。

要点

  • TAVR术后30天BNP比值每增加1点,全因死亡aHR 1.11(95%CI 1.07-1.15)。
  • 出院时BNP比值≥2者,出院至30天BNP比值每降低1点,全因死亡aHR 0.92(95%CI 0.88-0.96)。
  • 多数患者各随访时间点BNP比值>1,术后BNP升高与死亡和再住院独立相关。

核心结论

  • TAVR术后BNP水平升高与后续死亡和再住院风险独立相关。
  • 出院时BNP比值≥2者,出院至30天BNP比值下降与30天至2年全因死亡风险降低相关。

研究设计与样本

  • 队列研究,纳入PARTNER IIA、PARTNER IIB、SAPIEN 3中危和高危注册研究中接受TAVR的重度症状性主动脉瓣狭窄患者3391例。
  • 基线、出院、30天和1年测量BNP,计算BNP比值(实测BNP/所用检测正常上限),采用界标分析评估至2年结局。
  • 数据收集时间2011年4月至2019年1月。

主要发现

  • 3391例患者中1969例(58.1%)为男性,平均(SD)年龄82(7.5)岁。
  • BNP比值>1者占比:基线2820/3256(86.6%)、出院2652/2995(88.5%)、30天1779/2209(80.5%)、1年1799/2391(75.2%)。
  • 30天BNP比值每增加1点(约相当于BNP增加100 pg/mL),30天至2年全因死亡aHR 1.11(95%CI 1.07-1.15),心血管死亡aHR 1.16(95%CI 1.11-1.21),再住院aHR 1.08(95%CI 1.03-1.14)。
  • 出院时BNP比值≥2者,出院至30天BNP比值每降低1点,30天至2年全因死亡aHR 0.92(95%CI 0.88-0.96)。

临床怎么用

  • TAVR术后可测量BNP水平,用于识别后续死亡和再住院高风险患者。
  • 对出院时BNP比值≥2的患者,关注出院至30天BNP下降情况可能有助于风险分层。

局限性

  • 原文未报告局限性相关条目。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Among those with aortic stenosis, natriuretic peptide levels can provide risk stratification, predict symptom onset, and aid decisions regarding the timing of valve replacement. Less is known about the prognostic significance and potential clinical utility of natriuretic peptide levels measured after valve replacement. OBJECTIVE: To determine the associations of elevated B-type natriuretic peptide (BNP) levels after transcatheter aortic valve replacement (TAVR) and change in BNP levels between follow-up time points with risk of subsequent clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, patients with severe symptomatic aortic stenosis at intermediate, high, or prohibitive surgical risk for aortic valve replacement who underwent TAVR from the PARTNER IIA cohort, PARTNER IIB cohort, SAPIEN 3 intermediate-risk registry, and SAPIEN 3 high-risk registry were included. B-type natriuretic peptide levels were obtained at baseline and discharge as well as 30 days and 1 year after TAVR. For each measurement, a BNP ratio was calculated using measured BNP level divided by the upper limit of normal for the assay used. Outcomes were evaluated in landmark analyses out to 2 years. Data were collected from April 2011 to January 2019. MAIN OUTCOMES AND MEASURES: All-cause death, cardiovascular death, rehospitalization, and the combined end point of cardiovascular death or rehospitalization. RESULTS: Among 3391 included patients, 1969 (58.1%) were male, and the mean (SD) age was 82 (7.5) years. Most patients had a BNP ratio greater than 1 at each follow-up time point, including 2820 of 3256 (86.6%) at baseline, 2652 of 2995 (88.5%) at discharge, 1779 of 2209 (80.5%) at 30 days, and 1799 of 2391 (75.2%) at 1 year. After adjustment, every 1-point increase in BNP ratio at 30 days (approximately equivalent to an increase of 100 pg/mL in BNP) was associated with an increased hazard of all-cause death (adjusted hazard ratio [aHR], 1.11; 95% CI, 1.07-1.15), cardiovascular death (aHR, 1.16; 95% CI, 1.11-1.21), and rehospitalization (aHR, 1.08; 95% CI, 1.03-1.14) between 30 days and 2 years. Among those with a BNP ratio of 2 or more at discharge, after adjustment, every 1-point decrease in BNP ratio between discharge and 30 days was associated with a decreased hazard of all-cause death (aHR, 0.92; 95% CI, 0.88-0.96) between 30 days and 2 years. CONCLUSIONS AND RELEVANCE: Elevated BNP levels after TAVR was independently associated with increased subsequent mortality and rehospitalizations. Further studies to determine how best to mitigate this risk are warranted.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. O'Leary JM, Clavel MA, Chen S, et al. Association of Natriuretic Peptide Levels After Transcatheter Aortic Valve Replacement With Subsequent Clinical Outcomes. JAMA Cardiol. 2020. PMID: 32667623. doi:10.1001/jamacardio.2020.2614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。